Dimensional Fund Advisors LP Raises Stake in Altimmune, Inc. $ALT

Key Points

• Dimensional Fund Advisors increased its Altimmune stake by 268.7% in the first quarter, purchasing 762,223 additional shares to own 1.05 million shares valued at approximately $3.22 million.
• Institutional investors and hedge funds own 78.05% of Altimmune. The stock opened at $2.93, near its 52-week low of $2.56 and well below its 52-week high of $6.44.
• Analysts have a consensus “Moderate Buy” rating and an average price target of $14.33, despite Altimmune reporting a quarterly loss of $0.12 per share and continuing negative profitability metrics.

Dimensional Fund Advisors LP raised its holdings in Altimmune, Inc. (NASDAQ:ALT - Free Report) by 268.7% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,045,926 shares of the company's stock after purchasing an additional 762,223 shares during the quarter. Dimensional Fund Advisors LP owned about 0.80% of Altimmune worth $3,221,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the business. Arax Advisory Partners grew its holdings in shares of Altimmune by 99.7% during the fourth quarter. Arax Advisory Partners now owns 8,165 shares of the company's stock worth $29,000 after buying an additional 4,076 shares during the last quarter. SBI Securities Co. Ltd. grew its stake in shares of Altimmune by 27.9% in the 4th quarter. SBI Securities Co. Ltd. now owns 8,837 shares of the company's stock valued at $32,000 after purchasing an additional 1,928 shares during the last quarter. Quadrature Capital Ltd acquired a new position in shares of Altimmune in the fourth quarter valued at approximately $36,000. Victory Capital Management Inc. acquired a new position in shares of Altimmune in the third quarter valued at approximately $38,000. Finally, CreativeOne Wealth LLC purchased a new stake in shares of Altimmune during the fourth quarter worth approximately $38,000. Institutional investors and hedge funds own 78.05% of the company's stock.

Altimmune Stock Performance

NASDAQ ALT opened at $2.93 on Thursday. The company has a quick ratio of 29.56, a current ratio of 29.56 and a debt-to-equity ratio of 0.12. Altimmune, Inc. has a fifty-two week low of $2.56 and a fifty-two week high of $6.44. The business has a fifty day moving average of $2.90 and a 200-day moving average of $3.42. The stock has a market cap of $569.80 million, a price-to-earnings ratio of -3.15 and a beta of 0.27.

Altimmune (NASDAQ:ALT - Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($0.14) by $0.02. Altimmune had a negative return on equity of 42.57% and a negative net margin of 214,860.98%. As a group, analysts predict that Altimmune, Inc. will post -0.64 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ALT has been the subject of several recent research reports. Citizens Jmp decreased their price target on Altimmune from $14.00 to $11.00 and set a "market outperform" rating for the company in a report on Thursday, May 14th. Wall Street Zen upgraded shares of Altimmune from a "strong sell" rating to a "sell" rating in a research note on Saturday, June 27th. Leerink Partners initiated coverage on shares of Altimmune in a research report on Monday, June 22nd. They issued an "outperform" rating and a $10.00 price objective for the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Altimmune in a research report on Wednesday, June 24th. Finally, HC Wainwright reissued a "buy" rating on shares of Altimmune in a research note on Tuesday, July 28th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Altimmune currently has an average rating of "Moderate Buy" and a consensus target price of $14.33.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune's approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source